The long-term upward trend in the markets is marked; the S&P 500 is up 51% over the last 12 months, even taking into …
Election day is just around the corner, and Wall Street is placing its bet on a Democratic sweep. Following the Presidential debate on …
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
FBR’s George Zavoico looks ahead to CBIO’s next pivotal trial, bullish on CB 269d’s ability to lead to stable FIX activity into the mild hemophilia range.
OrbiMed Makes Big Bet on Xtant Medical Venture capital firm OrbiMed Advisors disclosed a 9.9%, or 1,952,670 shares, stake in Xtant Medical Holdings Inc …
Catalyst Biosciences Inc (NASDAQ:CBIO) investors came back from the hills after the drug maker announced that it has achieved a key milestone under its …
Shares of Catalyst Biosciences Inc (NASDAQ:CBIO) tumbled nearly 21% this morning after investors learned that the hematology company has priced an underwritten public offering …
Catalyst Biosciences Inc (NASDAQ:CBIO) is one of the most talked about stocks today. The biopharmaceutical company announced that the Korean Ministry of Food and Drug Safety …
On December 8, 2016, Catalyst Biosciences Inc (NASDAQ:CBIO) entered into a definitive agreement with Wyeth LLC, a wholly-owned subsidiary of Pfizer Inc. following …
